Medi M&M s.r.o. — Clinical Trial Site

14 Registered trials

4 Currently recruiting

Organisation

Medi M&M s.r.o.

Location

Moldava Nad Bodvou, Slovakia

Identifier

ORG-100045401

Address

Ceskoslovenskej Armady 35, 045 01, Slovakia

Departments

3031; Ambulancia vnútorného lekárstva, kardiologická ambulancia
6703: Interna a endokrinologicka amb
Ambulancia vnutorneho lekarstva
Cardiological ambulance
Cardiology Clinic
Interna ambulancia
Internal Ambulance
Kardiologická ambulancia
Kardiologická ambulancia a Interná ambulancia

Clinical trials at this site (14)

Search interface

ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting

2024-519712-13-00 Hypertriglyceridemia (HTG) 5 2025-12-08
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia at high risk of Acute Pancreatitis (SHASTA-5 Study) Recruiting

2024-518206-40-00 Severe hypertriglyceridemia (SHTG) 5 2025-11-03
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended

2023-509302-30-00 Hypertriglyceridemia 5 2024-11-04
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA 3 Study) Ended

2023-509300-14-00 Severe hypertriglyceridemia (SHTG) 5 2024-10-31
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
A Phase IIb Two-Cohort, Randomised, Placebo controlled, Double blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients with Ch… Ended

2023-510148-19-00 Chronic Heart Failure 4 2024-07-03
A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended

2023-505499-32-00 Uncontrolled hypertension (uTHN) defined as blood press 5 2024-03-08
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24